SAN DIEGO, Calif., June 30, 2017 /PRNewswire/ --CARsgen Therapeutics (CARsgen), a global pioneer
SAN DIEGO, Calif., June 30, 2017 /PRNewswire/ --CARsgen Therapeutics (CARsgen), a global pioneerfocused on developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced it has become the active member of The Alliance for Regenerative Medicine (ARM) as the first Chinese company of advanced therapy.
About CARsgen Therapeutics
CARsgen Therapeutics is a rapidly growing bio-tech start-up with the original CAR-T therapy discovery expertise, competitive GMP manufacturing capability, and global clinical development experience. CARsgen commit to deliver the most advanced yet affordable cell therapies to patients with unmet medical needs. With broad discovery pipeline across solid tumor and hematology malignancies, CARsgen proceeds the clinical development with a clear focus in CAR-T therapy for solid tumors. Founded in Nov 2014, CARsgen raised $30M in early 2016 in Series B. Four of its pioneering CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma (HCC), anti-GPC3 CAR-T for squamous lung cancer (SLC), cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM) and first-in-class anti-Claudin18.2-CAR-T for gastric and pancreatic cancer have all entered early clinical development.
For more information, please visit the website: www.carsgen.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/carsgen-therapeutics-joins-the-alliance-for-regenerative-medicine-300482448.html
SOURCE CARsgen Therapeutics
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All